0.80Open0.80Pre Close0 Volume2 Open Interest22.50Strike Price0.00Turnover263.92%IV112.59%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.80Extrinsic Value100Contract SizeAmericanOptions Type0.2429Delta0.0415Gamma13.70Leverage Ratio-0.0478Theta0.0013Rho3.33Eff Leverage0.0089Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet